Detalhe da pesquisa
1.
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study.
Pharmacoepidemiol Drug Saf
; 31(10): 1046-1055, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35791700
2.
Personalizing health care: feasibility and future implications.
BMC Med
; 11: 179, 2013 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23941275
3.
Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".
Biomed Res Int
; 2023: 9757348, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37065720
4.
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.
Front Pharmacol
; 13: 873556, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35865969
5.
Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
Front Med (Lausanne)
; 9: 940886, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36213666
6.
Comparison of Two Different Analgesic Prescription Strategies and Healthcare Systems: Slovenia vs. the Netherlands.
Front Pain Res (Lausanne)
; 2: 723797, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295498
7.
Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Appl Health Econ Health Policy
; 19(6): 915-927, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34553334
8.
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Biomed Res Int
; 2021: 9996193, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34676266
9.
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Expert Rev Pharmacoecon Outcomes Res
; 21(4): 527-540, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33535841
10.
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Appl Health Econ Health Policy
; 18(1): 5-16, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696433
11.
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Front Pharmacol
; 11: 591134, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33519450
12.
Integrative Review of Managed Entry Agreements: Chances and Limitations.
Pharmacoeconomics
; 38(11): 1165-1185, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32734573
13.
Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future.
Curr Med Res Opin
; 36(2): 301-327, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31794332
14.
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Expert Rev Pharmacoecon Outcomes Res
; 19(3): 251-261, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30696372
15.
Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications.
Front Pharmacol
; 9: 442, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29896100
16.
The European challenges of funding orphan medicinal products.
Orphanet J Rare Dis
; 13(1): 184, 2018 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396361
17.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Front Public Health
; 6: 328, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568938
18.
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
Pharmacoeconomics
; 35(12): 1271-1285, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28836222
19.
Policies for biosimilar uptake in Europe: An overview.
PLoS One
; 12(12): e0190147, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29284064
20.
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.
Front Pharmacol
; 8: 942, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29403372